

Date: 14th November, 2024

To,
The Corporate Relations Department,
Department of Corporate Services,
BSE Limited,
25th Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Sub. : Statement on Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations)

Ref.: Script Code -VAISHALI

Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please note that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Issuance of Equity Shares by way of conversion of Warrants of the Company during the Second Quarter ended September 30, 2024.

Please find enclosed herewith a statement in this regard.

The aforesaid statement has been reviewed by the Audit Committee and taken on record by the Board at their respective meetings held on 14th November, 2024

This is for your information and records please.

Thanking You,
Yours faithfully,
For and on behalf of

VAISHALI PHARMA LIMITED

**ATUL ARVIND VASANI
MANAGING DIRECTOR
DIN: 02107085**



Annexure A

**STATEMENT OF DEVIATION OR VARIATION IN UTILIZATION OF FUNDS
 RAISED**

Name Of Listed Entity	Vaishali Pharma Limited
Mode Of Fund Raising	Issuance of Equity Shares by way of conversion of Warrants
Date Of Raising Fund	16th July, 2024
Amount Raised	30,45,50,000
Report Filed for Quarter Ended	30th September, 2024
Monitoring Agency	Not Applicable
Monitoring Agency Name, If Applicable	Not Applicable
Is There a Deviation / Variation in Use of Funds Raised	No
If Yes, Whether the Same Is Pursuant to Change in Terms of a Contract or Objects, Which Was Approved by The Unit Holders	Not Applicable
If Yes, Date of Unit holders Approval	Not Applicable
Explanation For the Deviation / Variation	Not Applicable
Comments Of the Audit Committee After Review	No Comments
Comments Of the Auditor, If Any	No Comments

Set forth below are objects for which funds have been raised in the Issuance of Equity Shares through preferential issue and details of deviation, if any, in the following table:

Original Object	Modified Object, if any	Original Allocation (₹ in Rupees)	Modified Allocation, if any	Funds Utilised (₹ in Rupees)	Amount of Deviation / Variation for Quarter according to applicable	Remarks if any

					object	
The Company intends to raise funds for its future expansion and growth of the Company, through preferential issue.	NA	30,45,50,000	NA	30,45,50,000	NA	No

Deviation or variation could mean:

- Deviation in the objects or purposes for which the funds have been raised or
- Deviation in the amount of funds actually utilized as against what was originally disclosed
- Change in terms of a contract referred to in the fund-raising document i.e., prospectus, letter of offer, etc

VAISHALI PHARMA LIMITED

ATUL ARVIND VASANI
MANAGING DIRECTOR
 DIN: 02107085